Status:
UNKNOWN
Incidence of MIS-C and Other Complications Following SARS-CoV-2 Infection
Lead Sponsor:
Rigshospitalet, Denmark
Collaborating Sponsors:
Innovation Fund Denmark
Ministry of Education, Denmark
Conditions:
SARS CoV 2 Infection
Multisystem Inflammatory Disease, Pediatric, COVID-19 Related
Eligibility:
All Genders
Up to 17 years
Brief Summary
Multisystem inflammatory syndrome in children (MIS-C) is a rare severe complication to SARS-CoV-2 infection in children. It has been reported to occur in approximately one of 3,000 to 4,000 unvaccinat...
Detailed Description
AIM The project seeks to estimate the incidences of MIS-C in vaccinated and unvaccinated children and adolescents following variants delta and omicron, and other complications of SARS-CoV-2 including ...
Eligibility Criteria
Inclusion
- MIS-C according to criteria devised by the World Health Organization and Centers for Disease Control and Prevention (CDC)
- Invasive bacterial infections and viral infections secondary to SARS-CoV-2 or as consequence of SARS-CoV-2 lock down
Exclusion
- \-
Key Trial Info
Start Date :
July 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT05186597
Start Date
July 15 2021
End Date
December 31 2024
Last Update
February 23 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Copenhagen University Hospital Rigshospitalet
Copenhagen, Denmark, 2100